Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Rhea-AI Summary

Armata Pharmaceuticals' Chief Medical Officer to present at Phage Futures: Global Digital Summit 2023

Positive

• Armata Pharmaceuticals' presentation at Phage Futures may generate positive investor interest in their pathogen-specific bacteriophage therapeutics.

Negative

• None.

LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25^th.

Title:	Armata Clinical Trials Overview for Acute and Chronic Infections with Systemic and Local Phage Administration
Presenter:	Mina Pastagia, M.D., MS
	Chief Medical Officer
Time:	9:10am – 9:30am EDT (2:10pm – 2:30pm BST)
For more information or to register: https://www.kisacoresearch.com/events/phage-futures-digital

About Phage Futures: Global Digital Summit 2023

Phage Futures: Global Digital Summit 2023 is a stage upon which to initiate all-important discussions and forge partnerships between key stakeholders worldwide. The Summit is the leading platform accelerating the translation of bacteriophages into clinically and commercially viable therapeutics and tangible commercial solutions.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-presentation-at-phage-futures-global-digital-summit-2023-301961271.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

What is the event that Armata Pharmaceuticals' Chief Medical Officer will be presenting at?

The Chief Medical Officer of Armata Pharmaceuticals will be presenting at Phage Futures: Global Digital Summit 2023.

What is the focus of Armata Pharmaceuticals?

Armata Pharmaceuticals is focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

When will the presentation take place?

The presentation will take place on October 25th, from 9:10am to 9:30am EDT (2:10pm to 2:30pm BST).

Where can I find more information or register for the event?

More information and registration for the event can be found at https://www.kisacoresearch.com/events/phage-futures-digital.